Interim phase 1 results have sustained Checkpoint Therapeutics’ hopes for a second indication for its lead anti-PD-L1 antibody. The drug, cosibelimab, demonstrated a 54.8% objective response rate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results